Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. NB304295

HM74A/PUMA-G/GPR109A/NIACR1 Antibody (245106), PerCP, Novus Biologicals™
SDP

Catalog No. NB304295 Shop All R&D Systems Products
Change view
Click to view available options
Quantity:
0.5 mL
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
NB304295 0.5 mL
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. NB304295 Supplier Novus Biologicals Supplier No. FAB2760C
Add to Cart
Add to Cart

Description

Rat Monoclonal Antibody

HM74A/PUMA-G/GPR109A/NIACR1 Monoclonal specifically detects HM74A/PUMA-G/GPR109A/NIACR1 in Human samples. It is validated for CyTOF, Flow Cytometry.

Specifications

Antigen HM74A/PUMA-G/GPR109A/NIACR1
Applications CyTOF, Flow Cytometry
Classification Monoclonal
Clone 245106
Conjugate PerCP
Dilution Flow Cytometry, CyTOF-ready
Formulation PBS
Gene Alias GPR109A, HCA2, hydroxycarboxylic acid receptor 2, NIACR1
Host Species Rat
Immunogen NS0 mouse myeloma cell line transfected with human HM74A/GPR109A, Met1-Pro363, Accession # Q8TDS4
Purification Method Protein A or G purified from hybridoma culture supernatant
Quantity 0.5 mL
Regulatory Status RUO
Research Discipline GPCR
Primary or Secondary Primary
Gene ID (Entrez) 338442
Target Species Human
Content And Storage Store at 4C in the dark.
Form Purified
Isotype IgG2b
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.